Macro-to-micro (M2µ) Activity Apportionment for αRPT

αRPT 的宏观到微观 (M2µ) 活动分配

基本信息

  • 批准号:
    10713712
  • 负责人:
  • 金额:
    $ 49.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-19 至 2028-08-31
  • 项目状态:
    未结题

项目摘要

Recent advances in the targeted delivery of radionuclides and the increased availability of -emitters appropriate for clinical use have led to patient trials of multiple α-emitter radiopharmaceutical therapeutics (RPTs). One of these, Xofigo (223RaCl2) was FDA-approved and is in routine clinical practice, with many others likely to follow. One of the stated goals (pillars) of the NIH is a greater level of personalization in medicine. In the realm of radiopharmaceutical therapy (RPT) this translates directly as a need for more accurate personalized dosimetry in order to enable fractionation and administered activity tailored to each patient. However, current dosimetry paradigms are poorly suited to RPT. This reality is reflected by the discrepancies between clinical (or experimental) toxicity and expected toxicity calculated using standard organ-level (or voxel-level) dosimetry, including most notably: (a) hematotoxicity in 223Ra therapy of bone metastases, (b) renal and salivary gland toxicity in pre-clinical models and patients. The objective of this work is to create a dosimetric methodology more suited to αRPT, namely the Macro to micro (M2) methodology, which requires sub-organ activity apportionment factors for organs at risk. This will be accomplished via the following Aims: 1. In murine models, measure αRPT activity concentration in selected whole organs and in relevant organ sub-regions; generate apportionment factor histograms. The translation to human assumes that the link between macroscopic and microscopic spatiotemporal relationship for a given agent measured in a pre-clinical model will apply to the human as the distribution of the agent to the different microscopic compartments should remain the same. We will test and quantify the validity of this assumption and refine the human apportionment factors by introducing a third species, the mini-pig In Aim 2. We will assess apportionment factor transferability, by obtaining corresponding apportionment factor histograms for a porcine model. In Aim 3. We will demonstrate that M2µ predicts toxicity in the porcine model. 4. Apply the M2µ methodology to clinical trial data to quantify the potential benefit of personalized M2µ dosimetry and/or derive dose–response relationships. Successful completion of the proposal will reconcile experimental and clinical results not currently understood and provide a robust standardized dosimetry for personalized dosimetry-based treatment planning of αRPT. Such standardization will enable the dosimetry to be normalized to EQD2, thus enabling rational combinations with other RPTs or external beam therapy as well as relevant absorbed dose reporting. Here we plan to expand this approach to encompass the wide range of RPT/organ combinations that have either been shown to be or are potentially dose-limiting and that require the Macro to micro (M2) methodology to properly correlate dosimetry with toxicity thresholds and provide a deliverable that will allow end-users to convert macroscopically-measured activity to standardized dosimetry at the organ and (clinically relevant) sub-organ-level for a wide range of RPTs and correspondingly relevant organs.
放射性核素定向输送和 α 发射体可用性增加的最新进展 临床应用导致了多种 α 发射体放射性药物治疗 (RPT) 的患者试验。之一 其中,Xofigo (223RaCl2) 已获得 FDA 批准,并已进入常规临床实践,许多其他产品可能会跟进。 NIH 的既定目标(支柱)之一是提高医疗个性化水平。在领域 放射性药物治疗 (RPT) 这直接意味着需要更准确的个性化剂量测定 以便能够针对每位患者进行分段和管理活动。然而,目前的剂量测定 范式不太适合 RPT。这一现实反映在临床(或 实验)毒性和使用标准器官水平(或体素水平)剂量测定计算的预期毒性, 其中最值得注意的是:(a) 223Ra 骨转移治疗中的血液毒性,(b) 肾和唾液腺 临床前模型和患者的毒性。这项工作的目的是创建一种更有效的剂量测定方法 适合αRPT,即宏观到微观(M2)方法,需要子器官活动分配 危险器官的因素。这将通过以下目标来实现: 1. 在小鼠模型中,测量 αRPT 选定的整个器官和相关器官分区的活动浓度;生成分配因子 直方图。对人类的翻译假设宏观和微观之间的联系 在临床前模型中测量的给定药物的时空关系将适用于人类 药剂在不同微观室中的分布应保持相同。我们将测试并 量化这一假设的有效性,并通过引入第三个物种来完善人类分配因素, 目标 2 中的迷你猪。我们将评估分配因子的可转移性,通过获得相应的 猪模型的分配因子直方图。在目标 3 中,我们将证明 M2μ 可以预测毒性 猪模型。 4. 将 M2μ 方法应用于临床试验数据,以量化潜在益处 个性化 M2μ 剂量测定和/或得出剂量-反应关系。提案顺利完成 将协调目前尚未理解的实验和临床结果,并提供稳健的标准化 剂量测定用于基于剂量测定的个性化 αRPT 治疗计划。这种标准化将使 剂量测定将标准化为 EQD2,从而能够与其他 RPT 或外部束进行合理组合 治疗以及相关吸收剂量报告。在这里,我们计划扩展这种方法以涵盖 广泛的 RPT/器官组合已被证明具有或潜在的剂量限制性 需要宏观到微观 (M2) 方法将剂量测定与毒性阈值正确关联起来 提供可交付成果,允许最终用户将宏观测量的活动转换为标准化的活动 器官和(临床相关)亚器官水平的剂量测定,适用于各种 RPT 和相应的 有关机关。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert Francois Hobbs其他文献

Robert Francois Hobbs的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert Francois Hobbs', 18)}}的其他基金

Combination Radiopharmaceutical Therapy and External Beam Radiotherapy
放射药物治疗与外照射放射治疗的联合治疗
  • 批准号:
    10473785
  • 财政年份:
    2020
  • 资助金额:
    $ 49.89万
  • 项目类别:
Combination Radiopharmaceutical Therapy and External Beam Radiotherapy
放射药物治疗与外照射放射治疗的联合治疗
  • 批准号:
    10252753
  • 财政年份:
    2020
  • 资助金额:
    $ 49.89万
  • 项目类别:
Combination Radiopharmaceutical Therapy and External Beam Radiotherapy
放射药物治疗与外照射放射治疗的联合治疗
  • 批准号:
    10668390
  • 财政年份:
    2020
  • 资助金额:
    $ 49.89万
  • 项目类别:
Modeling Targeted Alpha Particle Therapy of Cancer
癌症靶向阿尔法粒子治疗建模
  • 批准号:
    8295112
  • 财政年份:
    2012
  • 资助金额:
    $ 49.89万
  • 项目类别:
Modeling Targeted Alpha Particle Therapy of Cancer
癌症靶向阿尔法粒子治疗建模
  • 批准号:
    8468664
  • 财政年份:
    2012
  • 资助金额:
    $ 49.89万
  • 项目类别:
Modeling Targeted Alpha Particle Therapy of Cancer
癌症靶向阿尔法粒子治疗建模
  • 批准号:
    8658040
  • 财政年份:
    2012
  • 资助金额:
    $ 49.89万
  • 项目类别:
Dose-Response in Radionuclide Therapy
放射性核素治疗的剂量反应
  • 批准号:
    10436212
  • 财政年份:
    2006
  • 资助金额:
    $ 49.89万
  • 项目类别:
Dose-Response in Radionuclide Therapy
放射性核素治疗的剂量反应
  • 批准号:
    10200681
  • 财政年份:
    2006
  • 资助金额:
    $ 49.89万
  • 项目类别:
Dose-Response in Radionuclide Therapy
放射性核素治疗的剂量反应
  • 批准号:
    9594370
  • 财政年份:
    2006
  • 资助金额:
    $ 49.89万
  • 项目类别:

相似海外基金

Alpha particles combined with ATR inhibition to activate the immune system: mechanisms and pre-clinical translation
Alpha 粒子结合 ATR 抑制激活免疫系统:机制和临床前转化
  • 批准号:
    10636348
  • 财政年份:
    2023
  • 资助金额:
    $ 49.89万
  • 项目类别:
Long range detection of alpha particles.
阿尔法粒子的远距离检测。
  • 批准号:
    ST/W005050/1
  • 财政年份:
    2022
  • 资助金额:
    $ 49.89万
  • 项目类别:
    Training Grant
Elucidation of unusual nano-effects on dissolution, aggregation and denaturation processes of alpha particles generated by fuel debris retrieval
阐明燃料碎片回收产生的α粒子溶解、聚集和变性过程中异常纳米效应
  • 批准号:
    EP/X022218/1
  • 财政年份:
    2022
  • 资助金额:
    $ 49.89万
  • 项目类别:
    Research Grant
Integrated modelling of burning plasmas with a reduced transport model for alpha particles
燃烧等离子体的集成建模与α粒子的简化传输模型
  • 批准号:
    15K18311
  • 财政年份:
    2015
  • 资助金额:
    $ 49.89万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
SHINE: Self-Consistent Resonant-Cyclotron Heating of Protons and Alpha Particles in the Solar Wind and Solar Corona
SHINE:太阳风和日冕中质子和阿尔法粒子的自洽共振回旋加热
  • 批准号:
    1358103
  • 财政年份:
    2014
  • 资助金额:
    $ 49.89万
  • 项目类别:
    Continuing Grant
Basic Study to evaluate DNA Damage and Cell Survival with Alpha-Particles from Astatine-211
使用 Astatine-211 的 α 粒子评估 DNA 损伤和细胞存活的基础研究
  • 批准号:
    26461866
  • 财政年份:
    2014
  • 资助金额:
    $ 49.89万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study of the alpha cluster gas-like state in 12C via the measurement of the multiple decay alpha particles
通过多次衰变α粒子的测量研究12C中的α团簇气态
  • 批准号:
    24740139
  • 财政年份:
    2012
  • 资助金额:
    $ 49.89万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Theoretical study on dynamics of 12C synthesis through radiative capture reactions of three alpha-particles
三种α粒子辐射捕获反应合成12C动力学的理论研究
  • 批准号:
    24540261
  • 财政年份:
    2012
  • 资助金额:
    $ 49.89万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of ripple resonance diffusion of alpha particles in burning plasma
燃烧等离子体中α粒子的波纹共振扩散分析
  • 批准号:
    21560856
  • 财政年份:
    2009
  • 资助金额:
    $ 49.89万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
NSWP: Kinetic Turbulence-Driven Solar Wind Model Through the Resonant Cyclotron Interaction - Protons and Alpha Particles
NSWP:通过共振回旋加速器相互作用的动力学湍流驱动的太阳风模型 - 质子和阿尔法粒子
  • 批准号:
    0719738
  • 财政年份:
    2007
  • 资助金额:
    $ 49.89万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了